S&P 500   3,118.88 (-0.05%)
DOW   28,012.74 (+0.03%)
QQQ   202.62 (-0.14%)
CGC   14.68 (-4.24%)
BABA   186.55 (+0.57%)
GE   11.38 (-1.22%)
T   39.31 (-0.51%)
ACB   2.50 (-8.44%)
F   8.95 (+0.00%)
PRI   130.40 (-0.17%)
BAC   32.89 (-0.12%)
DIS   148.03 (+2.32%)
S&P 500   3,118.88 (-0.05%)
DOW   28,012.74 (+0.03%)
QQQ   202.62 (-0.14%)
CGC   14.68 (-4.24%)
BABA   186.55 (+0.57%)
GE   11.38 (-1.22%)
T   39.31 (-0.51%)
ACB   2.50 (-8.44%)
F   8.95 (+0.00%)
PRI   130.40 (-0.17%)
BAC   32.89 (-0.12%)
DIS   148.03 (+2.32%)
S&P 500   3,118.88 (-0.05%)
DOW   28,012.74 (+0.03%)
QQQ   202.62 (-0.14%)
CGC   14.68 (-4.24%)
BABA   186.55 (+0.57%)
GE   11.38 (-1.22%)
T   39.31 (-0.51%)
ACB   2.50 (-8.44%)
F   8.95 (+0.00%)
PRI   130.40 (-0.17%)
BAC   32.89 (-0.12%)
DIS   148.03 (+2.32%)
S&P 500   3,118.88 (-0.05%)
DOW   28,012.74 (+0.03%)
QQQ   202.62 (-0.14%)
CGC   14.68 (-4.24%)
BABA   186.55 (+0.57%)
GE   11.38 (-1.22%)
T   39.31 (-0.51%)
ACB   2.50 (-8.44%)
F   8.95 (+0.00%)
PRI   130.40 (-0.17%)
BAC   32.89 (-0.12%)
DIS   148.03 (+2.32%)
Log in

Proteostasis Therapeutics Stock Price, Forecast & Analysis (NASDAQ:PTI)

$1.08
+0.03 (+2.86 %)
(As of 11/18/2019 11:10 AM ET)
Today's Range
$1.08
Now: $1.08
$1.09
50-Day Range
$0.72
MA: $0.84
$1.08
52-Week Range
$0.61
Now: $1.08
$6.48
Volume2,800 shs
Average Volume1.16 million shs
Market Capitalization$55.22 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.59
Proteostasis Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers and develops novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company's lead product candidates include cystic fibrosis transmembrane conductance regulator (CFTR) modulators comprising PTI-428, an amplifier, which has completed Phase II study; and PTI-801, a third generation corrector molecule and PTI-808, a potentiator molecule, which has completed Phase I study. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PTI
CUSIPN/A
Phone617-225-0096

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.84 million
Book Value$1.37 per share

Profitability

Net Income$-61,830,000.00

Miscellaneous

Employees48
Market Cap$55.22 million
Next Earnings Date3/13/2020 (Estimated)
OptionableOptionable

Receive PTI News and Ratings via Email

Sign-up to receive the latest news and ratings for PTI and its competitors with MarketBeat's FREE daily newsletter.


Proteostasis Therapeutics (NASDAQ:PTI) Frequently Asked Questions

What is Proteostasis Therapeutics' stock symbol?

Proteostasis Therapeutics trades on the NASDAQ under the ticker symbol "PTI."

How were Proteostasis Therapeutics' earnings last quarter?

Proteostasis Therapeutics Inc (NASDAQ:PTI) posted its earnings results on Thursday, November, 7th. The company reported ($0.25) earnings per share for the quarter, topping analysts' consensus estimates of ($0.40) by $0.15. View Proteostasis Therapeutics' Earnings History.

When is Proteostasis Therapeutics' next earnings date?

Proteostasis Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, March 13th 2020. View Earnings Estimates for Proteostasis Therapeutics.

What price target have analysts set for PTI?

3 equities research analysts have issued twelve-month price targets for Proteostasis Therapeutics' stock. Their forecasts range from $5.00 to $14.00. On average, they expect Proteostasis Therapeutics' share price to reach $9.50 in the next year. This suggests a possible upside of 804.8% from the stock's current price. View Analyst Price Targets for Proteostasis Therapeutics.

What is the consensus analysts' recommendation for Proteostasis Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Proteostasis Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Proteostasis Therapeutics.

What are Wall Street analysts saying about Proteostasis Therapeutics stock?

Here are some recent quotes from research analysts about Proteostasis Therapeutics stock:
  • 1. According to Zacks Investment Research, "Proteostasis Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery and development of novel therapeutics to treat diseases caused by an imbalance in the proteostasis network primarily in the United States. Proteostasis Therapeutics, Inc. is based in Cambridge, Massachusetts. " (11/13/2019)
  • 2. Cantor Fitzgerald analysts commented, ": We reiterate our OW rating and are lowering out 12-month PT to $14 from $21 on Proteostasis (due to lowering the probability of success on the program from 55% to 40%). This morning, the company announced and hosted a conference call to provide results from the low- and high-dose data from the triplet (PTI-801/808/428) trial. Additionally, the company announced data from the combination studies of on top of SYMDEKO. We feel the results were inferior to our projections, but believe data by year-end 2019 could make the case whether PTI’s internal drugs could be a competitive entrant in cystic fibrosis (CF)." (3/25/2019)

Has Proteostasis Therapeutics been receiving favorable news coverage?

Media headlines about PTI stock have trended very negative this week, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Proteostasis Therapeutics earned a news impact score of -3.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for Proteostasis Therapeutics.

Are investors shorting Proteostasis Therapeutics?

Proteostasis Therapeutics saw a drop in short interest in the month of October. As of October 31st, there was short interest totalling 1,380,000 shares, a drop of 41.5% from the September 30th total of 2,360,000 shares. Based on an average trading volume of 559,700 shares, the short-interest ratio is presently 2.5 days. Currently, 3.8% of the shares of the stock are sold short. View Proteostasis Therapeutics' Current Options Chain.

Who are some of Proteostasis Therapeutics' key competitors?

What other stocks do shareholders of Proteostasis Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Proteostasis Therapeutics investors own include BHP Group (BHP), Rite Aid (RAD), Idera Pharmaceuticals (IDRA), Micron Technology (MU), Syndax Pharmaceuticals (SNDX), Clearside Biomedical (CLSD), Resonant (RESN), New Age Beverages (NBEV), OrganiGram (OGI) and vTv Therapeutics (VTVT).

Who are Proteostasis Therapeutics' key executives?

Proteostasis Therapeutics' management team includes the folowing people:
  • Ms. Meenu Chhabra, Pres, CEO & Director (Age 47)
  • Dr. Benito Munoz, Chief Scientific Officer (Age 57)
  • Dr. Po-Shun Lee, Exec. VP & Chief Medical Officer (Age 50)
  • Ms. Sandra Zimmerman, VP of Fin., Principal Financial Officer & Principal Accounting Officer
  • Ms. Sheila Gilbride Wilson, Chief Operating Officer

When did Proteostasis Therapeutics IPO?

(PTI) raised $51 million in an initial public offering (IPO) on Thursday, February 11th 2016. The company issued 3,900,000 shares at $12.00-$14.00 per share. Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Baird and H.C. Wainwright & Co. were co-managers.

How do I buy shares of Proteostasis Therapeutics?

Shares of PTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Proteostasis Therapeutics' stock price today?

One share of PTI stock can currently be purchased for approximately $1.05.

How big of a company is Proteostasis Therapeutics?

Proteostasis Therapeutics has a market capitalization of $53.69 million and generates $2.84 million in revenue each year. The company earns $-61,830,000.00 in net income (profit) each year or ($1.61) on an earnings per share basis. Proteostasis Therapeutics employs 48 workers across the globe.View Additional Information About Proteostasis Therapeutics.

What is Proteostasis Therapeutics' official website?

The official website for Proteostasis Therapeutics is http://www.proteostasis.com/.

How can I contact Proteostasis Therapeutics?

Proteostasis Therapeutics' mailing address is 80 Guest Street Suite 500, Boston MA, 02135. The company can be reached via phone at 617-225-0096 or via email at [email protected]


MarketBeat Community Rating for Proteostasis Therapeutics (NASDAQ PTI)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  263 (Vote Outperform)
Underperform Votes:  316 (Vote Underperform)
Total Votes:  579
MarketBeat's community ratings are surveys of what our community members think about Proteostasis Therapeutics and other stocks. Vote "Outperform" if you believe PTI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel